.png)
Biobeat
Cuffless wearable patch for continuous BP and multi-vital RPM with AI early-warning
Latest event found: 13 Jan 2026 · 9 months ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Biobeat is shifting from technology validation toward U.S. commercialization, supported by a major Series B financing and an integration partnership targeting cardiac-recovery monitoring. Its strategy centers on scaling a cuffless, patch-worn ambulatory blood-pressure platform through clinical and device-industry channels.
Efficiency Ratio
The company appears highly capital-efficient in technical differentiation, but its small employee base relative to commercialization ambitions suggests execution capacity will depend on converting recent financing into sales, regulatory, and deployment infrastructure.
Evidence Signals
Biobeat and Kestra announced an exclusive license and co-development arrangement to integrate Biobeat blood-pressure monitoring into Kestra’s ASSURE wearable cardioverter defibrillator system; Kestra also committed a $5 million equity investment.
Biobeat closed a $50 million Series B equity financing led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, with participation from a strategic investor; proceeds are intended to expand U.S. commercialization.
Background · older than 12 months
Biobeat received 510(k) clearance for its latest cuffless blood-pressure monitoring device, enabling continued U.S. commercialization of the patch-worn ambulatory monitoring system.
- About
- Israeli medical-device company (Biobeat Technologies Ltd.; HQ Petah Tikva/Tel Aviv, Israel with operations in Boca Raton, Florida), founded in 2016 by Arik Ben Ishay. Makes wireless, cuffless wearable monitors — a chest patch and a wrist device — that use photoplethysmography (PPG) to track blood pressure, SpO2, pulse, respiration, temperature, and cardiac output/stroke volume, feeding a cloud platform with an AI-based Early Warning Score for patient deterioration. It holds the first-ever FDA clearance for cuffless PPG-only blood pressure, is the first FDA-cleared cuffless 24-hour ambulatory BP monitor (ABPM), and is CE-marked. Raised a $50M Series B (Dec 2025, led by Ally Bridge/OrbiMed/Elevage) to expand US commercialization. Continuous wearable vitals + deterioration scoring map to the casualty-monitoring / prolonged-field-care thread of C12; defense relevance is commercial-first.
- Tags
- #wearable #cuffless #bloodpressure #abpm #ppg #rpm #ews #fda #vitals #patch